US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

In trials, the PPAR agonists were effective in reducing progression of PBC ... a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation NEWTON, Mass.--(BUSINESS ...

Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia ...

Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, ...